Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Serdar Farhan

Interventional Cardiology New York, NY Medical Doctor

NPI 1417495508 CMS profile 8775424

1 Gustave L Levy Pl, New York, NY 10029

Open in the dashboard

General payments

$30,987

544 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Serdar Farhan of New York, NY is reported in the CMS Open Payments database as having received $30,987 across 544 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,817 44
2024 General $978 18
2023 General $2,935 42
2022 General $9,293 190
2021 General $5,756 176
2020 General $2,209 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Serdar Farhan
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Serdar Farhan were reported at $9,817. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Serdar Farhan Interventional Cardiology median Middle half National median
2019 $0 $1,097 $329–$3,048 $163
2020 $2,209 $473 $161–$1,480 $114
2021 $5,756 $677 $233–$1,827 $132
2022 $9,293 $978 $333–$2,724 $149
2023 $2,935 $1,136 $382–$2,986 $160
2024 $978 $1,181 $395–$3,326 $164
2025 $9,817 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Medtronic, Inc. $9,429 53 payments
  2. Abbott Laboratories $4,285 83 payments
  3. Shockwave Medical, Inc $4,255 73 payments
  4. Boston Scientific Corporation $2,048 25 payments
  5. Edwards Lifesciences Corporation $986 12 payments
  6. Ancora Heart, Inc. $943 5 payments
  7. Amgen Inc. $832 29 payments
  8. Cardiovascular Systems Inc. $809 18 payments
  9. Biotronik Inc. $794 18 payments
  10. Terumo Medical Corporation $618 20 payments
  11. Other $5,987 208 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $20,625 513 payments
  2. Travel and Lodging $10,036 23 payments
  3. Education $327 8 payments
Products named General payments · program years 2020–2025
  1. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $2,680 35 payments
  2. OMNILINK ELITE $1,530 15 payments
  3. Vascular Lithotripsy $1,361 31 payments
  4. VersaCross Access Solution $1,161 9 payments
  5. AccuCinch $943 5 payments
  6. Repatha $832 29 payments
  7. PK Papyrus $661 17 payments
  8. XARELTO $568 22 payments
  9. LifeVest $546 26 payments
  10. COREVALVE EVOLUT R $421 3 payments
  11. Other $13,972 387 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

1,490

Median for Interventional Cardiology: 2,236

Drug cost

$241,052

Median for Interventional Cardiology: $380,412

Branded share of claims

26.2%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 83 $91,142
Eliquis Apixaban Brand 45 $42,117
Entresto Sacubitril/Valsartan Brand 33 $29,246
Farxiga Dapagliflozin Propanediol Brand 46 $28,150
Brilinta Ticagrelor Brand 19 $14,665
Xarelto Rivaroxaban Brand 11 $9,691
Praluent Pen Alirocumab Brand 14 $6,752
Repatha Sureclick Evolocumab Brand 12 $6,315
Ezetimibe Generic 67 $1,806
Atorvastatin Calcium Generic 173 $1,479

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$32,729

Medicare's payments for the services billed

Medicare patients

118

Average age 77

Services billed

285

62 women, 56 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 64%
Diabetes 54%
Arthritis 52%
Chronic kidney disease 51%
Atrial fibrillation 42%
Depression 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $69
$69 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

544 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record